CAR-T Market Report, 321 Pages
March 2023 – 2023 Version Now Live!
CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.”
T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of our immune system and play a key role in directing the immune response and killing cells infected by pathogens. In CAR-T cell therapy, blood is drawn from the patient and the T-cells are separated out. In the laboratory, a disarmed virus is then used to genetically engineer the T-cells to produce chimeric antigen receptors (CARs) on their surface. Once infused into the patient, these CARs enable the T-cells to recognize and attach to an antigen on the cancer cell, leading to its destruction.
CAR-T Cell Therapy Market
Scientific progress within the field of cancer immunotherapy has led to six CAR-T cell therapy approvals by the U.S. FDA, including:
- Kymriah (tisagenlecleucel)
- Yescarta (axicabtagene ciloleucel)
- Tecartus (brexucabtagene autoleucel)
- Breyanzi (lisocabtagene maraleucel)
- Abecma (idecabtagene vicleucel)
- Carvykti (Ciltacabtagene autoleucel)
In addition, Relma-cel’s (Relmacabtagene) received approval from the NMPA in China.
Unfortunately, the blood cancers treatable by the currently approved CAR-T cell therapies represent less than 5% of cancer patients worldwide. At present, there are over 1,100 ongoing CAR-T clinical trials focusing on solutions to other types of blood cancers and solid tumors, which represent the other 95% of cancer cases. This growth in the number of clinical trials has been fueled by the unprecedented 90% remission rate shown by most of the approved CAR-T therapies.
These historic approvals demonstrate that the CAR-T market has arrived and is taking the biotech industry by storm. This has driven CAR-T funding to staggering new heights. At first the trend was subtle, but the tide has swelled as CAR-T start-ups have been richly funded by investors eager to get into this rapidly expanding area of regenerative medicine.
Additionally, there has been over $100 billion of market capitalization from CAR-T companies in recent years. Financing rounds by CAR-T companies have approached $4 billion, while CAR-T industry partnerships have contributed an astounding $2 billion. M&A activity has been even more aggressive, with Celgene snagging Juno Therapeutics for $9 billion and Bristol-Myers Squibb (BMS) acquiring Celgene for $74B. Gilead’s acquisition of Kite Pharma for $11.9 billion also made waves, as did other transactions, such as Astellas Pharma’s acquisition of Xyphos Biosciences and its CAR-T technology for $665 million.
This billion dollar market would not have been possible without the remarkable efficacy of the early CAR-T therapies in treating several types of blood cancers. Ranging from small start-ups to billion-dollar companies, CAR-T companies are proliferating in all healthcare markets worldwide.
Recently released, this 321-page report reveals:
- CAR-T market size determinations with segmentation by product, geography, and indication, as well as future forecasts through 2028
- Detailed coverage of the approved CAR-T products, including regulatory approvals, pricing, reimbursement, and market penetration
- Clinical trial activity by type, geography, phase and sponsor
- Comprehensive CAR-T patent analysis, including top inventors, patent holders, patent types, geographies, and most cited patents
- CAR-T industry mergers and acquisitions, IPOs, and financing events
- Deal-making, strategic partnerships, and co-commercialization agreements within the CAR-T sector
- Little known market trends, future directions, and emerging opportunities
- Profiles of leading CAR-T competitors composing the global marketplace
- And so much more
This global strategic report will position you to:
- Capitalize on rapidly emerging trends
- Optimize decision-making
- Reduce company risk
- Approach partners/investors for collaboration or funding
- Implement an informed and advantageous business strategy in 2023
Although progressing at breakneck speed, developments within the field of CAR-T cell therapy are still early stage, positioning the market for remarkable expansion. Today is similar to the launch of the first chemotherapy treatments, when oncologists started treating patients with a single type of chemotherapy. Now, fifty years later, cancer patients are treated with over a hundred different chemotherapy agents. In the same way, we will soon have numerous CAR-T therapies available to treat liquid cancers, solid tumors, and autoimmune diseases, as well as inflammatory conditions.
TABLE OF CONTENTS: Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials & Trends, 2023
With an online readership of nearly one million viewers per year, BioInformant is a U.S. market research firm with 15 years of experience. As the first and only market research firm to specialize in the cell therapy industry, BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine. Headquartered near Washington, DC, BioInformant is strategically positioned to be near the National Institutes of Health (NIH), U.S. FDA, Maryland Biotech Corridor, and policy makers on Capital Hill. Serving all-star clients that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in cell therapy industry data. For more information, read Client Testimonials here.
The content within this report was compiled using a diverse range of sources, as described in this Research Methodology.
Remember, all BioInformant products come with a Greater Than 100% Money Back Guarantee. If the strategies and tools aren’t helpful to you – we’ll cheerfully refund your money, and you can keep the product.
Have questions? Email us at [email protected] to get a rapid reply. Checkout below to get immediate access to this report, with printing rights allowed.